The protein Z/protein Z-dependent protease inhibitor complex: Systemic or local control of coagulation?

Hamostaseologie

Volumn 31, Issue 3, 2011, Pages 155-164

  Vasse, M ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

Cancer; Protein Z; Protein Z dependent protease inhibitor; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; FATTY ACID BINDING PROTEIN; FIBRIN; PROTEIN Z DEPENDENT PROTEASE INHIBITOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; BLOOD CLOTTING; CANCER CELL; FETUS WASTAGE; GENE; GENETICS; HUMAN; INFLAMMATION; KIDNEY; NONHUMAN; PROTEIN INTERACTION; REVIEW;

ANIMALS; BLOOD COAGULATION; BLOOD PROTEINS; HEMOSTASIS; HUMANS; MICE; PROTEASE INHIBITORS; SERPINS; THROMBOSIS;

EID: 80052439448     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1161     Document Type: Review

References (97)

1. Sejima H, Hayashi T, Deyashiki Y et al. Primary structure of vitamin K-dependent human protein Z. Biochem Biophys Res Commun 1990; 171: 661-668.
2. Han X, Fiehler R, Broze GJ Jr. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci USA 1998; 95: 9250-9255.
3. Tabatabai A, Fiehler R, Broze GJ Jr. Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb Haemost 2001; 85: 655-660.
4. Yin Z-F, Huang ZF, Cui J et al. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci USA 2000; 97: 6734-6738.
5. Zhang J, Tu Y, Lu L et al. Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood 2008; 111: 4973-4978.
6. Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000; 96: 3049-3055.
7. Vasse M. Protein Z, a protein seeking a pathology. Thromb Haemost 2008; 100: 548-556.
8. Corral J, González-Conejero R, Hernández-Espinosa D et al. Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol 2007; 137: 99-108.
9. Sofi F, Cesari F, Abbate R et al. A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost 2010; 103: 749-756.
10. Miletich JP, Broze GJ Jr. Human plasma protein Z antigen: range in normal subjects and effect of warfarine therapy. Blood 1987; 69: 1580-1586.
11. Souri M, Koseki-Kuno S, Iwata H et al. A naturally occurring E30Q mutation in the Gla domain of protein Z causes its impaired secretion and subsequent deficiency. Blood 2005; 105: 3149-3154.
12. Iwata H, Souri M, Kemkes-Matthes B et al. An additional Glu30Lys substitution in the Gla domain of the protein Z gene is not a common polymorphism but a rare mutation, which would cause its deficiency. J Thromb Haemost 2005; 3: 2360-2361.
13. Souri M, Iwata H, Zhang WG et al. Unique secretion mode of human protein Z: its Gla domain is responsible for inefficient, vitamin K-dependent and warfarin-sensitive secretion. Blood 2009; 113: 3857-3864.
14. Booth SL, Al Rajabi A. Determinants of vitamin K status in humans. Vitam Horm 2008; 78: 1-22.
15. Cleuren AC, Van der Linden IK, De Visser YP et al. 17a-Ethinylestradiol rapidly alters transcript levels of murine coagulation genes via estrogen receptor a. J Thromb Haemost 2010; 8: 1838-1846.
16. Al-Shanqeeti A, van Hylckama Vlieg A, Berntorp E et al. Protein Z and protein Z-dependent protease inhibitor. Determinants of levels and risk of venous thrombosis. Thromb Haemost 2005; 93: 411-413.
17. Santacroce R, Cappucci F, Di Perna P et al. Protein Z gene polymorphisms are associated with protein Z plasma levels. J Thromb Haemost 2004; 2: 1197-1199.
18. Ravi S, Mauron T, Lämmle B et al. Protein Z in healthy human individuals and in patients with a bleeding tendency. Br J Haematol 1998; 102: 1219-1223.
19. Heeb MJ, Fisher M, Paganini-Hill A. Association of low protein Z levels with ischemic stroke in young women. Thromb Haemost 2007; 97: 495-496.
20. Forastiero RR, Martinuzzo ME, Lu L et al. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost 2003; 1: 1764-1770.
21. Fujimaki K, Yamazaki T, Taniwaki M et al. The gene for human protein Z is localized to chromosome 13 at band q34 and is coded by eight regular exons and one alternative exon. Biochemistry 1998; 37: 6838-6846.
22. Vasse M, Denoyelle C, Legrand E et al. Weak regulation of protein Z biosynthesis by inflammatory cytokines. Thromb Haemost 2002; 87: 350-351.
23. Vossen CY, Hasstedt SJ, Rosendaal FR et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2004; 2: 242-247.
24. Rice GI, Futers TS, Grant PJ. Identification of novel polymorphisms within the protein Z gene, haplotype distribution and linkage analysis. Thromb Haemost 2001; 85: 1123-1124.
25. Lichy C, Kropp S, Dong-Si T et al. A common polymorphism of the protein Z gene is associated with protein Z plasma levels and with risk of cerebral ischemia in the young. Stroke 2004; 35: 40-45.
26. Santacroce R, Sarno M, Cappucci F et al. Low protein Z levels and risk of occurrence of deep vein thrombosis. J Thromb Haemost 2006; 4: 2417-2422
27. Le Cam-Duchez V, Barbay V, Bal Dit Sollier C et al. Haplotypic or genotypic combinations of three protein Z polymorphisms influence protein Z plasma level. Thromb Haemost 2009; 101: 212-214.
28. Nowak-Göttl U, Fröhlich B, Thedieck S et al. Association of the protein Z ATG haplotype with symptomatic nonvascular stroke or thromboembolism in white children: a family-based cohort study. Blood 2009; 113: 2336-2341.
29. Staton J, Sayer M, Hankey GJ et al. Protein Z gene polymorphisms, protein Z concentrations, and ischemic stroke. Stroke 2005; 36: 1123-1127.
30. Kemkes-Matthes B, Matthes KJ, Souri M et al. R255h amino acid substitution of protein Z identified in patients with factor V Leiden mutation. Br J Haematol 2005; 128: 248-252.
31. Corral J, González-Conejero R, Soria JM et al. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood 2006; 108: 177-183.
32. Sofi F, Cesari F, Tu Y et al. Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients. J Thromb Haemost 2009; 7: 731-735.
33. 2+ binding properties of the gamma-carboxyglutamic acid-containing module of protein Z in the intact protein and in N-terminal fragments. FEBS Lett 1992; 314: 5-9.
34. Ichinose A, Takeya H, Espling E et al. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res Commun 1990; 172: 1139-1144.
35. Rezaie AR, Bae JS, Manithody C et al. Protein Z-dependent protease inhibitor binds to the C-terminal domain of protein Z. J Biol Chem 2008; 283: 19922-19926.
36. Wei Z, Yan Y, Carrell RW et al. Crystal structure of protein Z-dependent inhibitor complex shows how protein Z functions as a cofactor in the membrane inhibition of factor X. Blood 2009; 114: 3662-3667.
37. Huang X, Dementiev A, Olson ST et al. Basis for the specificity and activation of the serpin protein Z-dependent proteinase inhibitor (ZPI) as an inhibitor of membrane-associated factor Xa. J Biol Chem 2010; 285: 20399-20409.
38. Han X, Huang ZF, Fiehler R et al. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 1999; 38: 11073-11078.
39. Huang X, Swanson R, Broze GJ Jr et al. Kinetic characterization of the protein Z-dependent protease inhibitor reaction with blood coagulation factor Xa. J Biol Chem 2008; 283: 29770-29783.
40. Huang X, Rezaie AR, Broze GJ Jr et al. Heparin is a major activator of the anticoagulant serpin, protein Z-dependent protease inhibitor. J Biol Chem 2011; 286: 8740-8751.
41. Rezaie AR, Manithody C, Yang L. Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor: both active site and exosite interactions are required for inhibition. J Biol Chem 2005; 280: 32722-32728.
42. Vasse M, Guegan-Massardier E, Borg JY et al. Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet 2001; 357: 933-934.
43. Kemkes-Matthes B, Nees M, Kühnel G et al. Protein Z influences the prothrombotic phenotype in factor V Leiden patients. Thromb Res 2002; 106: 183-185.
44. Pardos-Gea J, Ordi-Ros J, Serrano S et al. Protein Z levels and anti-protein Z antibodies in patients with arterial and venous thrombosis. Thromb Res 2008; 121: 727-734.
45. Martinelli I, Razzari C, Biguzzi E et al. Low levels of protein Z and the risk of venous thromboembolism. J Thromb Haemost 2005; 3: 2817-2819.
46. Heeb MJ, Paganini-Hill A, Griffin JH et al. Low protein Z levels and risk of ischemic stroke: differences by diabetic status and gender. Blood Cells Mol Dis 2002; 29: 139-144.
47. Undar L, Karadogan I, Oztürk F. Plasma protein Z levels inversely correlate with plasma interleukin-6 levels in patients with acute leukemia and non-Hodgkin's lymphoma. Thromb Res 1999; 94: 131-134.
48. McQuillan AM, Eikelboom JW, Hankey GJ et al. Protein Z in ischemic stroke and its etiologic subtypes. Stroke 2003; 34: 2415-2419.
49. Cesari F, Fatini C, Sticchi E et al. Protein Z gene polymorphisms (intron F 79 G>A; -13 A>G) are not associated with acute coronary syndromes. Thromb Haemost 2006; 96: 98-99.
50. Le Cam-Duchez V, Soria C, Dit Sollier CB et al. Rare genotypes of protein Z gene are a risk factor for premature myocardial infarction but not protein Z plasma level. Thromb Haemost 2009; 102: 131-136.
51. Marjot T, Yadav S, Hasan N et al. Genes associated with adult cerebral venous thrombosis. Stroke 2011; 42: 913-918.
52. Le Cam-Duchez V, Bagan-Triquenot A, Barbay V et al. The G79A polymorphism of protein Z gene is an independent risk factor for cerebral venous thrombosis. J Neurol 2008; 255: 1521-1525.
53. Refaai MA, Ahn C, Lu L et al. Protein Z and ZPI levels and cardiovascular events. J Thromb Haemost 2006; 4: 1628-1629.
54. Van de Water N, Tan T, Ashton F et al. Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol 2004; 127: 190-194.
55. Razzari C, Martinelli I, Bucciarelli P et al. Polymorphisms of the protein Z-dependent protease inhibitor (ZPI) gene and the risk of venous thromboembolism. Thromb Haemost 2006; 95: 909-910.
56. Dentali F, Gianni M, Lussana F et al. Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism: a meta-analysis. Br J Haematol 2008; 143: 284-287.
57. Gris JC, Quéré I, Dechaud H et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood 2002; 99: 2606-2608.
58. Richani K, Romero R, Kim YM et al. Tissue microarray: an effective high-throughput method to study the placenta for clinical and research purposes. J Matern Fetal Neonatal Med 2006; 19: 509-515.
59. Nien JK, Romero R, Hoppensteadt D et al. Pyelonephritis during pregnancy: a cause for an acquired deficiency of protein Z. J Matern Fetal Neonatal Med 2008; 21: 629-637.
60. Grandone E, Colaizzo D, Cappucci F et al. Protein Z levels and unexplained fetal losses. Fertil Steril 2004; 82: 982-983.
61. Gris JC, Amadio C, Mercier E et al. Anti-protein Z antibodies in women with pathologic pregnancies. Blood 2003; 101: 4850-4852.
62. Sater MS, Finan RR, Al-Hammad SA et al. High frequency of anti-protein Z IgM and IgG autoantibodies in women with idiopathic recurrent spontaneous miscarriage. Am J Reprod Immunol 2011; 65: 526-531.
63. Sailer T, Vormittag R, Koder S et al. Clinical significance of anti-protein Z antibodies in patients with lupus anticoagulant. Thromb Res 2008; 122: 153-160.
64. Erez O, Romero R, Vaisbuch E et al. Maternal antiprotein Z antibodies in pregnancies complicated by pre-eclampsia, SGA and fetal death. J Matern Fetal Neonatal Med 2009; 22: 662-671.
65. Gris JC, Mercier E, Quéré I et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-3699.
66. Dossenbach-Glaninger A, van Trotsenburg M, Helmer H et al. Association of the protein Z intron F G79A gene polymorphism with recurrent pregnancy loss. Fertil Steril 2008; 90: 1155-1160.
67. El-Hamid SA, El-Khayat W. Relationship of the protein Z intron F G79A and IL6 C634G gene polymorphisms with the risk of recurrent pregnancy loss in Egyptian women. J Investig Med 2011.
68. Topalidou M, Effraimidou S, Farmakiotis D et al. Low protein Z levels, but not the intron F G79A polymorphism, are associated with unexplained pregnancy loss. Thromb Res 2009; 124: 24-27.
69. Grandone E, Colaizzo D, Cappucci F et al. An unreported mutation within protein Z gene is associated with very low protein levels in women with fetal loss. Fertil Steril 2008; 90: 864-865.
70. Grandone E, Favuzzi G, De Stefano V et al. Protein Z g-42a variant and the risk of pregnancy-related venous thromboembolism in a cohort of Italian patients. Thromb Res 2009; 123: 848-850.
71. Fedi S, Sofi F, Brogi D, Tellini I et al. Low protein Z plasma levels are independently associated with acute coronary syndromes. Thromb Haemost 2003; 90: 1173-1178.
72. Cesari F, Gori AM, Fedi S et al. Modifications of protein Z and interleukin-6 during the acute phase of coronary artery disease. Blood Coagul Fibrinolysis 2007; 18: 85-86.
73. Vasse M, Denoyelle C, Corbière C et al. Human endothelial cells synthesize protein Z, but not the protein Z dependent inhibitor. Thromb Haemost 2006; 95: 519-523.
74. Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost 2001; 86: 8-13.
75. Aydin F, Yilmaz M, Ozdemir F et al. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 2002; 25: 570-572.
76. Sousou T, Khorana A. Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie 2009; 29: 121-124.
77. Shang Y, Pan XY, Ding CP et al. Clinical significance of protein Z detection in patients with malignant tumors. Ai Zheng 2005; 24: 1144-1147.
78. Vairaktaris E, Serefoglou Z, Yapijakis C et al. Coagulation-related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer. Anticancer Res 2007; 27: 2449-2451.
79. Eroglu A, Ozturk A, Cam R et al. Intron F G79A polymorphism of the protein Z gene in cancer patients with and without thrombosis. J Thromb Thrombolysis 2009; 27: 204-206.
80. Capurso G, Lattimore S, Crnogorac-Jurcevic T et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer 2006; 13: 541-558.
81. Leja J, Essaghir A, Essand M et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol 2009; 22: 261-272.
82. Sierko E, Wojtukiewicz MZ, Ostrowska-Cichocka K et al. Protein Z-dependent protease inhibitor (ZPI) is present in loco in human breast cancer tissue. Thromb Haemost 2010; 104: 183-185.
83. Sierko E, Wojtukiewicz MZ, Zimnoch L et al. Protein Z is present in human breast cancer tissue. Int J Hematol 2011: doi 10.1007/s12185-011-0846-3.
84. Broze GJ Jr, Tu Y. Protein Z and protein Z-dependent protease inhibitor and renal tubules. Thromb Haemost 2010; 103: 473-474.
85. Kaneko K, Yamanobe T, Nakagomi K et al. Detection of protein Z in a renal calculus composed of calcium oxalate monohydrate with the use of liquid chromatography-mass spectrometry/mass spectrometry following two-dimensional polyacrylamide gel electrophoresis separation. Anal Biochem 2004; 324: 191-196.
86. Freue GV, Sasaki M, Meredith A et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics 2010; 9: 1954-1967.
87. Ishiguro K, Kojima T, Kadomatsu K et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 873-878.
88. Jalbert LR, Rosen ED, Moons L et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998; 102: 1481-1488.
89. Saller F, Brisset AC, Tchaikovski SN et al. Generation and phenotypic analysis of protein S-deficient mice. Blood 2009; 114: 2307-2314.
90. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
91. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001; 184: 258-274.
92. Grebe MT, Luu B, Sedding D et al. Fibrinogen promotes early atherosclerotic changes of the carotid artery in young, healthy adults. J Atheroscler Thromb 2010; 17: 1003-1008.
93. Greten J, Kreis I, Liliensiek B et al. Localisation of protein Z in vascular lesions of patients with atherosclerosis. Vasa 1998; 27: 144-148.
94. Bernik MB, Kwaan HC. Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest 1969; 48: 1740-1753.
95. Tkachuk VA, Plekhanova OS, Parfyonova YV. Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol 2009; 87: 231-251.
96. Mengele K, Harbeck N, Reuning U et al. Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2. Hämostaseologie 2005; 25: 301-310.
97. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 2004; 30: 31-44.